Phase I Dose-Escalation Study of Azacitidine (Vidaza) and Bortezomib (Velcade) in T-Cell Lymphoma.

Trial Profile

Phase I Dose-Escalation Study of Azacitidine (Vidaza) and Bortezomib (Velcade) in T-Cell Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2013

At a glance

  • Drugs Bortezomib (Primary) ; Azacitidine
  • Indications Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Post-transplant lymphoproliferative disorder; Sezary syndrome; T cell lymphoma; T cell prolymphocytic leukaemia
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 19 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 21 Nov 2011 Company Millennium and Celgene Corporation added to the associations field as reported by ClinicalTrials.gov.
    • 21 Nov 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top